An increased expression of CD163 via abatacept treatment can promote the macrophage maturation process towards the M2 phenotype, restoring the M1/M2 disequilibrium associated with the chronic inflammation of RA [161]. This evidence concerns the gene CD163 and rheumatoid arthritis.